Author: Ophthalmology

Clinical Measurement of the Angle of Ocular Movements in the Nine Cardinal Positions of Gaze – Corrected Proof

Purpose: To measure the maximum angle of ocular versions using photographs of the 9 cardinal positions and a modified limbus test.Design: An evaluation of diagnostic technology; a prospective observational study.Participants: We enrolled 104 healthy subjects, 20 to 40 years of age.Methods: Photographs were obtained in the 9 cardinal positions of gaze and the images were processed using Photoshop. The images were analyzed using the Image J program to measure the angle of version. The maximum angle of the 9 cardinal positions was quantified using a modified limbus test.Main Outcome Measures: We measured the maximum angle of ocular versions in the (Read more...)

Gonioscopy-Assisted Transluminal Trabeculotomy, A Novel Ab Interno Trabeculotomy: Technique Report and Preliminary Results – Corrected Proof

Purpose: To introduce a novel, minimally invasive, ab interno approach to a circumferential 360-degree trabeculotomy and to report the preliminary results.Design: Retrospective, noncomparative cases series.Participants: Eighty-five eyes of 85 consecutive patients who sought treatment at Glaucoma Associates of Texas with uncontrolled open-angle glaucoma and underwent gonioscopy-assisted transluminal trabeculotomy (GATT) for whom there was at least 6 months of follow-up data.Methods: Retrospective chart review of patients who underwent GATT by 4 of the authors (D.S.G., D.G.G., O.S., R.L.F.) between October 2011 and October 2012. The surgery was performed in adults with various open-angle glaucomas.Main Outcome Measures: Intraocular pressure (IOP), glaucoma medications, (Read more...)

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration – Corrected Proof

Purpose: We sought to determine the most cost-effective treatment for patients with newly diagnosed neovascular macular degeneration: monthly or as-needed bevacizumab injections, or monthly or as-needed ranibizumab injections.Design: Cost-effectiveness analysis.Participants: Hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration.Methods: Using a mathematical model with a 20-year time horizon, we compared the incremental cost-effectiveness of treating a hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration using monthly bevacizumab, as-needed bevacizumab, monthly ranibizumab, or as-needed ranibizumab. Data came from the Comparison of Age-related macular degeneration Treatment Trial (CATT), the Medicare Fee Schedule, and the medical literature.Main Outcome (Read more...)

Proton Therapy for Uveal Melanoma in 43 Juvenile Patients: Long-Term Results – Corrected Proof

Purpose: To examine the metastatic and survival rates, eye retention probability, and the visual outcomes of juvenile patients after proton beam radiotherapy (PBRT) for uveal melanoma (UM).Design: Retrospective case-factor matched control study.Participants and Controls: Forty-three patients younger than 21 years treated with PBRT for UM were compared with 129 matched adult control patients.Methods: Information on patient demographics and clinical characteristics were recorded before and after treatment from patients’ files. The control group was composed of adult patients (>21 years) matched for tumor size (largest tumor diameter, ±2 mm; height, ±2 mm) and anterior margin location (iris, ciliary body, pre-equatorial or (Read more...)

Assessment of Iris Surface Features and Their Relationship with Iris Thickness in Asian Eyes – Corrected Proof

Purpose: To assess iris surface features in Asian eyes and examine their associations with iris thickness measured by anterior segment optical coherence tomography (AS OCT).Design: Cross-sectional study.Participants: We recruited 250 subjects from the Singapore Malay Eye Study.Methods: We obtained standardized slit-lamp photographs and developed a grading system assessing iris crypts (by number and size), furrows (by number and circumferential extent), and color (higher grade denoting darker iris). Vertical and horizontal cross-sections of the anterior chamber were imaged using AS OCT. Intragrader and intergrader agreements in the grading of iris surface were assessed by weighted κ (κw) statistic. Associations of the (Read more...)

Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical Trials – Corrected Proof

Purpose: To characterize preinjection intraocular pressure (IOP) in eyes receiving monthly ranibizumab versus sham or verteporfin photodynamic therapy (PDT) for age-related macular degeneration (AMD).Design: Post hoc analysis of IOP data from 2 phase 3 clinical trials, the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial.Participants: All safety-evaluable patients who received 1 or more injections of sham or PDT or of ranibizumab and had 1 or more postbaseline IOP measurements recorded for the study eye.Methods: Preinjection IOP measurements (Read more...)

A Randomized, Controlled Trial of Corneal Collagen Cross-Linking in Progressive Keratoconus: Three-Year Results – Corrected Proof

Purpose: To report the refractive, topographic, and clinical outcomes 3 years after corneal collagen cross-linking (CXL) in eyes with progressive keratoconus.Design: Prospective, randomized controlled trial.Participants: One hundred eyes with progressive keratoconus were randomized into the CXL treatment or control groups.Methods: Cross-linking was performed by instilling riboflavin 0.1% solution containing 20% dextran for 15 minutes before and during the 30 minutes of ultraviolet A irradiation (3 mW/cm2). Follow-up examinations were arranged at 3, 6, 12, 24, and 36 months.Main Outcome Measures: The primary outcome measure was the maximum simulated keratometry value (Kmax). Other outcome measures were uncorrected visual acuity (UCVA; measured (Read more...)

期刊一览

Shah (p. 352) 等人分析了肺癌葡萄膜转移患者的临床特征、治疗及预后。 他们发现,44%葡萄膜转移癌患者在转移灶发现时并未诊断出肺癌。另外,他们还发现,尽管现阶段的眼部治疗方案可以尽…

A Simple Vista en Este Número

Shah y otros (p. 352) evaluaron las características, el tratamiento y el pronóstico clínico de pacientes con metástasis uveal por cáncer de pulmón. Encontraron que 44% de los pacientes con metástasis uveal no habían sido diagnosticados con cán…

This Issue At A Glance

Shah et al (p. 352) assessed the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer. They found that 44% of patients with uveal metastasis had not been diagnosed with lung cancer at the time the metastasis w…

Corrigendum

With apologies from the authors of “Preterm Birth and Later Retinal Detachment: A Population-Based Cohort Study of More than 3 Million Children and Young Adults” (Ophthalmology 2013;120:2278-2285), the 6th paragraph on the 2nd column (p. 2280) shou…

Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration – Corrected Proof

Purpose: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the assoc…